NASDAQ:REPL 21 October 2025

FDA Decision on Replimune (NASDAQ:REPL) Prompts $763 Million in Melanoma Stock Shifts

A positive FDA decision triggered the movement of nearly $763 million between two melanoma stocks on Friday. Replimune Group saw an increase of around $486 million, while Iovance Biotherapeutics lost approximately $277 million. These figures are based on the most recent common-share counts reported by the companies.

3 August 2026

Biotechnology·NASDAQ:IOVA·NASDAQ:REPL·Pharmaceuticals·Stock Market

Replimune (NASDAQ:REPL) Shares Soar as FDA Panel Supports RP1 Despite Ongoing Evidence Debate

Replimune stock finished Friday at $11.20, gaining 107.0%. The surge came after an FDA advisory panel voted 10–3 in favor of RP1. The company's reported market capitalization jumped by about $485 million to $940.2 million. Trading volume was 33.38 million shares, 7.5 times the usual level.

31 July 2026

Biotechnology·NASDAQ:REPL·Pharmaceuticals·Stock Market

Replimune (NASDAQ:REPL) Shares Surge, Gaining Nearly $600 Million in Equity Value Following FDA Decision

Replimune stock surged approximately 131% to near $12.50 ahead of Friday’s regular trading. A panel of FDA advisers voted 10-3 in favor of RP1’s IGNYTE efficacy data being interpretable and clinically important.

31 July 2026

Biotechnology·NASDAQ:REPL·Stock Market

Replimune Stock Rockets 100% on FDA Nod – Analysts Eye Upside

Replimune’s stock has been extremely volatile in 2025. It soared on Oct. 20 after the FDA acceptance news: shares nearly doubled from about $4.50 to $8.94 that day marketbeat.com. This reversed a mid-year collapse – in July 2025 a disappointing FDA Complete Response Letter caused the stock to collapse ~73% in one day globenewswire.com. Over the past year the 52-week trading range is roughly $2.68 to $17.00 marketbeat.com, reflecting that roller-coaster.

21 October 2025

NASDAQ:REPL·Stock Market

NASDAQ:REPL 21 October 2025 - 3 August 2026

FDA Decision on Replimune (NASDAQ:REPL) Prompts $763 Million in Melanoma Stock Shifts

Replimune (NASDAQ:REPL) Shares Soar as FDA Panel Supports RP1 Despite Ongoing Evidence Debate

Replimune (NASDAQ:REPL) Shares Surge, Gaining Nearly $600 Million in Equity Value Following FDA Decision

Replimune Stock Rockets 100% on FDA Nod – Analysts Eye Upside

TechStock² Updates

Nu Holdings Shares Surge 10% on Strong Margin Recovery, $1 Billion Profit Recorded

Beyond Meat Stock Rises After Reverse Split, but Nasdaq Test Is Not Over

Rithm Capital’s Newrez settlement amounts to $0.02 per share while regulatory scrutiny persists

Dollar Drops While Weak U.S. Sales Meet Oil’s 6% Weekly Gain

Intuitive Machines Shares Rise 9% on $1.8 Billion Order Backlog Ahead of Challenging Second-Half Sales Period

Top Stock Picks

AerCap

Uber

Taiwan Semiconductor

dLocal

Tapestry

Live updates

Investment Disclaimer